Clinical trials: Blood Protein Disorders
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hemophilia B
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
This study will examine the long-term safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children and adults with severe hemophilia B.
- Trial name
- NCT02053792
- Testing
- rIX-FP
- Where
- 42 sites in United States, Australia and 13 more
- Volunteers
- 97 people
- Sponsor
- CSL Behring
Hemophilia A
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.
- Trial name
- NCT03205163
- Testing
- Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose)
- Where
- 10 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bioverativ, a Sanofi company
Multiple Myeloma
CT Antigen TCR-Engineered T Cells for Myeloma
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
- Trial name
- NCT01892293
- Testing
- Treatment with NY-ESO-1c259-modified T cells
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adaptimmune
Hemophilia A
Russian Kogenate Pediatric Study
A prospective study to evaluate the effect of rFVIII-FS in different prophylactic regimens on bleeding events frequency and development of arthropathy in Previously Treated and Minimally treated Hemophilia A pediatric population.
- Trial name
- NCT00632814
- Testing
- rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week, rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg), rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
- Where
- 4 sites in Russia
- Volunteers
- 32 people
- Sponsor
- Bayer
Diphtheria, Tetanus
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00313911
- Testing
- DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib
- Where
- 2 sites in Mexico, Peru
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Waldenstrom's Macroglobulinemia
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
This research study is evaluating a drug called idelalisib (formerly known as GS-1101 or CAL-101) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02439138
- Testing
- GS-1101
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
This randomized phase I/II trial studies the side effects and the best dose of temsirolimus when given together with bortezomib, rituximab, and dexamethasone and to see how well they work compared to bortezomib, rituximab, and…
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT01381692
- Testing
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Multiple Myeloma
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT03837509
- Testing
- INCB001158, Daratumumab SC
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.
- Trial name
- NCT02079519
- Testing
- Bevacizumab
- Where
- 4 sites in Austria
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma, Diarrhea
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.
- Trial name
- NCT03767257
- Testing
- Colesevelam Pill
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
The purpose of the research study is to determine the response rates when Revlimid® is combined with Doxil® and Dexamethasone (Dd-R) in newly diagnosed Multiple Myeloma.
- Trial name
- NCT00617591
- Testing
- Lenalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
The purpose of this study is to determine whether this disease will get better if treated with higher doses of Lenalidomide even if the disease returns while taking low doses of Lenalidomide.
- Trial name
- NCT01463670
- Testing
- lenalidomide
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma for patients who have received at least one prior therapy.
- Trial name
- NCT00128921
- Testing
- VELCADE™
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Arkansas
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Multiple Myeloma
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and…
- Trial name
- NCT01109004
- Testing
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Where
- 54 sites in United States
- Volunteers
- 758 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
Investigators planned to accrue 176 participants, to compare the response rate, overall response rate and survival of patients with multiple myeloma (MM) when randomized to two regimens (thalidomide+Dexamethasone versus…
- Trial name
- NCT00215943
- Testing
- zoledronic acid, dexamethasone, thalidomide
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Hemophilia A
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
This multicenter, open-label, Phase 3 study with randomized and non-randomized arms is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII…
- Trial name
- HAVEN 5 (NCT03315455)
- Testing
- Emicizumab
- Where
- 13 sites in China, Hong Kong and 2 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.